Holen Sie sich die Stockscreener-App
501.76
2.71%
10.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$491.70
Offen:
$500
24-Stunden-Volumen:
52,808
Relative Volume:
0.06
Marktkapitalisierung:
$38.21B
Einnahmen:
$3.93B
Nettoeinkommen (Verlust:
$894.97M
KGV:
46.37
EPS:
10.82
Netto-Cashflow:
$837.70M
1W Leistung:
+6.30%
1M Leistung:
+29.18%
6M Leistung:
+18.52%
1J Leistung:
-0.94%
1-Tages-Spanne:
$498.53
$507.83
1-Wochen-Bereich:
$465.00
$507.83
52-Wochen-Spanne:
$356.14
$548.88
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Vergleichen Sie IDXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
501.52 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
TMO
Thermo Fisher Scientific Inc
|
421.45 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
194.96 | 141.27B | 23.82B | 3.77B | 4.90B | 5.15 |
|
A
Agilent Technologies Inc
|
113.24 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.23 | 26.35B | 15.50B | 1.33B | 2.16B | 7.34 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $577 From $566, Maintains Outperform Rating - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable - simplywall.st
Idexx outlines 2025 growth with 6-9% organic revenue target amid innovation launches - MSN
IDEXX Laboratories (IDXX) Announces Key Amendments to Corporate Structure - GuruFocus
IDEXX Laboratories Updates Corporate Governance Structure - TipRanks
Here’s Why Baron Focused Growth Fund Invested in IDEXX Laboratories (IDXX) - Insider Monkey
IDEXX Laboratories (IDXX) Target Price Raised by Morgan Stanley | IDXX Stock News - GuruFocus
BTIG Raises Price Target on IDEXX Laboratories to $545 From $530, Maintains Buy Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $558 From $548, Maintains Overweight Rating - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2025 Earnings Call Transcript - Insider Monkey
IDEXX Laboratories [NasdaqGS:IDXX] Raises 2025 Guidance and Reports Q1 Growth in Revenue and EPS - Yahoo Finance
Leerink Partners Adjusts IDEXX Laboratories Price Target to $515 From $500 - marketscreener.com
IDEXX Laboratories Announces First Quarter Results | IDXX Stock News - GuruFocus
IDEXX Laboratories (IDXX) Surpasses Q1 Expectations with Robust Earnings - GuruFocus
IDEXX Laboratories Inc (IDXX) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid ... - Yahoo Finance
IDEXX Laboratories Inc (IDXX) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid Market Challenges - GuruFocus
IDEXX Laboratories Reports Strong Q1 2025 Results - TipRanks
Idexx: Q1 Earnings Snapshot - CT Insider
IDEXX Laboratories’ Earnings Call: Strong Growth Amid Challenges - TipRanks
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) CEO Compensation Looks Acceptable To Us And Here's Why - simplywall.st
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Lab jumps after Q1 beat and guidance raise - MSN
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
Stifel Adjusts Price Target for Idexx Laboratories (IDXX) Following Q1 Results | IDXX Stock News - GuruFocus
IDEXX Laboratories (IDXX) Surges After Lifting 2025 Outlook on F - GuruFocus
IDEXX Laboratories stock jumps on Q1 beat (IDXX:NASDAQ) - Seeking Alpha
IDEXX Laboratories (IDXX) Reports Strong Start to 2025 with Reve - GuruFocus
IDEXX Laboratories Ups Profit Forecast Thanks To Pet Care Demand - Finimize
Earnings call transcript: IDEXX Labs Q1 2025 EPS beats forecast, stock surges - Investing.com
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market - TradingView
IDEXX beats the Street on Q1 results, raises 2025 outlook - Mainebiz
Does IDEXX Laboratories (NASDAQ:IDXX) Deserve A Spot On Your Watchlist? - Yahoo Finance
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics - marketscreener.com
IDEXX (IDXX) Reports Q1 Revenue Exceeding Expectations | IDXX St - GuruFocus
IDEXX Laboratories Q1 Earnings, Revenue Increase; 2025 Outlook Raised - marketscreener.com
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates - Yahoo Finance
IDEXX Laboratories Q1 2025 Earnings: EPS of $2.96 Beats Estimate - GuruFocus
IDEXX Laboratories Inc Q1 Profit Advances, Beats Estimates - Nasdaq
IDEXX LABS Earnings Results: $IDXX Reports Quarterly Earnings - Nasdaq
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 EPS $2.96, vs. FactSet Est of $2.85 - marketscreener.com
IDEXX Labs earnings beat by $0.05, revenue fell short of estimates - Investing.com South Africa
IDEXX Laboratories Announces First Quarter Results - TradingView
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss? - TradingView
Here's How Much $100 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth Today - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term - Yahoo
Animal Health Diagnosis Market Is Booming So Rapidly with IDEXX Laboratories, Zoetis - openPR.com
Earnings Preview: What to Expect From IDEXX Laboratories' Report - MSN
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.94%
3.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):